We are live on ! Find out more
ACP

Altitude Crest Partners Portfolio holdings

AUM $234M
This Fund
S&P 500
This Quarter Est. Return
+28.94%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$234M
AUM Growth
+$84.1M
Cap. Flow
+$79.3M
Cap. Flow %
33.93%
Top 10 Hldgs %
69.27%
Holding
34
New
22
Increased
2
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
STVN icon
Stevanato
STVN
+$16.7M
2
AVBP icon
ArriVent BioPharma
AVBP
+$11.2M
3
TMO icon
Thermo Fisher Scientific
TMO
+$10.3M
4
GPCR icon
Structure Therapeutics
GPCR
+$8.65M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.61M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$11.2M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11M
3
EXAS
Exact Sciences
EXAS
+$7.33M
4
BBIO icon
BridgeBio Pharma
BBIO
+$4.85M
5
ROIV icon
Roivant Sciences
ROIV
+$3.81M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
26
Zymeworks
ZYME
$1.75B
$1.53M 0.66%
+145,581
New +$1.62M
MGX icon
27
Metagenomi Therapeutics
MGX
$45.9M
$1.41M 0.6%
+133,333
New +$1.53M
TRML
28
DELISTED
Tourmaline Bio
TRML
$1.09M 0.46%
+47,400
New +$1.67M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$36.4B
$29.9K 0.01%
+200
New +$33.4K
SRZNW icon
30
Surrozen Inc Warrant
SRZNW
$12.5K 0.01%
384,573
– –
ARGX icon
31
argenx
ARGX
$52.9B
– –
-29,500
Closed -$11.2M
BMRN icon
32
BioMarin Pharmaceuticals
BMRN
$11.4B
– –
-114,042
Closed -$11M
EXAS
33
DELISTED
Exact Sciences
EXAS
– –
-99,130
Closed -$7.33M
AMAM
34
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-43,100
Closed -$614K
1
2

Similar funds

APWM
Atlas Private Wealth Management Albany, New York $238M AUM 17.48% 1-Year Est. Return
SWM
Soundmark Wealth Management Kirkland, Washington $225M AUM 17.51% 1-Year Est. Return
CC
Cipher Capital New York $216M AUM 23.63% 1-Year Est. Return
HI
Handelsinvest Investeringsforvaltning Herning, Denmark $208M AUM 35.27% 1-Year Est. Return
CC
Codex Capital New York $205M AUM 65.13% 1-Year Est. Return
DAM
Derbend Asset Management Peachtree City, Georgia $203M AUM 22.97% 1-Year Est. Return
BG
Benedetti & Gucer Atlanta, Georgia $201M AUM 25.95% 1-Year Est. Return
VLC
Van Leeuwen & Company Princeton, New Jersey $197M AUM 44.16% 1-Year Est. Return

Altitude Crest Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Altitude Crest Partners held 34 positions worth $234M, up 56% from $149M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Altitude Crest Partners deployed $79.3M of net new capital in Q1 2024, opening 22 new positions and adding to 2 existing holdings. Its largest new stake was Stevanato: 550,000 shares worth $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $4.85M trimmed.

  • Altitude Crest Partners's largest Q1 2024 buy was Stevanato: 550,000 shares worth $17.7M.
  • Altitude Crest Partners added most to Apellis Pharmaceuticals in Q1 2024, an estimated $8.61M increase.
  • Altitude Crest Partners's biggest Q1 2024 reduction was BridgeBio Pharma, cutting an estimated $4.85M.
  • Altitude Crest Partners fully exited argenx in Q1 2024, selling an estimated $11.2M.
  • Altitude Crest Partners's ten largest holdings make up 69% of its $234M portfolio in Q1 2024.
  • Altitude Crest Partners opened 22 new positions and closed 4 in Q1 2024.
  • Altitude Crest Partners's portfolio value rose 56% quarter-over-quarter to $234M.

Based on Altitude Crest Partners's 13F filing for Q1 2024, filed 14 May 2024.